Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 6601978396

Countries

Italy

Activities

Collapse all

Employment (6)

University of Chieti-Pescara: Pescara, IT

2020-12-01 to present | Clinical research (ObGyn)
Employment
Source: Self-asserted source
Claudio Celentano

Università degli Studi G. d'Annunzio Chieti - Pescara: Chieti, Italy/ Abruzzo, IT

2007-01-01 to 2020-11-30 | researcher (Ob-Gyn dept)
Employment
Source: Self-asserted source
Claudio Celentano

Ausl Pescara: Penne, IT

2002-09-01 to 2006-12-31 | Specialist (OB GYN Dept)
Employment
Source: Self-asserted source
Claudio Celentano

Azienda Sanitaria Locale 2 Lanciano Vasto Chieti: Chieti, Abruzzo, IT

2002-05-01 to 2002-08-31 | Specialist (OB GYN Dept)
Employment
Source: Self-asserted source
Claudio Celentano

ASL Campobasso: Campobasso, Italia, IT

2001-07-03 to 2002-04-30 | Specialist (OB GYN)
Employment
Source: Self-asserted source
Claudio Celentano

AUSL Pescara: Penne, IT

2000-03-16 to 2001-07-02 | Specialist (OB GYN dept)
Employment
Source: Self-asserted source
Claudio Celentano

Education and qualifications (4)

University G. d'Annunzio: Chieti, Italy, IT

2000-12-01 to 2004-12-04 | Board Specialist (Human Genetic Institute)
Education
Source: Self-asserted source
Claudio Celentano

University G.d'Annunzio: Chieti, Italy, IT

1995-10-01 to 1999-11-23 | Board Specialist (Ob-Gyn Dept)
Education
Source: Self-asserted source
Claudio Celentano

Tel Aviv University: Holon, Israel, IL

1997-12-01 to 1998-08-15 | Post-doctoral fellowship (Ob Gyn Dept)
Education
Source: Self-asserted source
Claudio Celentano

University G. d'Annunzio: Chieti, Italy, IT

1988-09-07 to 1994-11-13 | MD (School of Medicine)
Education
Source: Self-asserted source
Claudio Celentano

Peer review (27 reviews for 4 publications/grants)

Review activity for European journal of obstetrics & gynecology and reproductive biology (4)
Review activity for European journal of obstetrics, gynecology, and reproductive biology. (19)
Review activity for Heliyon. (3)
Review activity for Placenta. (1)
How many people are using ORCID?